The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Sanofi
Consulting or Advisory Role - Blueprint Medicines; MSD
Speakers' Bureau - Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
 
Evan J. Lipson
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Genentech; Macrogenics; Merck; Millennium; Novartis; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst); Sysmex (Inst)
Patents, Royalties, Other Intellectual Property - METHOD OF PREVENTING ORGAN TRANSPLANT REJECTIONS USING AGONISTS TO THE PD-1 CHECKPOINT PATHWAY (Inst)
 
Hussein Abdul-Hassan Tawbi
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Merck; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; Lunaphore Technologies; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Luis Matamala
Speakers' Bureau - Bristol-Myers Squibb
Expert Testimony - Bristol-Myers Squibb
 
Erika Castillo Gutiérrez
No Relationships to Disclose
 
Piotr Rutkowski
No Relationships to Disclose
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Bristol-Myers Squibb; MSD Oncology; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Christopher D. Lao
Consulting or Advisory Role - BMS; Immunocore
Research Funding - Bristol-Myers Squibb; Dynavax Technologies; Genentech
Travel, Accommodations, Expenses - BMS; Immunocore
 
Juliana Janoski de Menezes
No Relationships to Disclose
 
Stéphane Dalle
Employment - Sanofi Pasteur (I)
Stock and Other Ownership Interests - Sanofi (I)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); MSD (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ana Maria Arance
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Roche; Roche/Genentech; Sanofi; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Shivani Srivastava
Employment - Bristol-Myers Squibb
 
Mena Abaskharoun
Employment - Bristol-Myers Squibb
 
Katy L. Simonsen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Bin Li
Employment - Bristol-Myers Squibb; Pfizer
Stock and Other Ownership Interests - Bristol-Myers Squibb; Pfizer
 
Georgina V. Long
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Skyline Diagnostics; Specialised Therapeutics
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Checkpoint THerapeutics; Compass Therapeutics; Eisai; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche